NTLA — INTELLIA THERAPEUTICS Share News
0.000.00%
Last trade - 00:00- $1.56bn
- $1.13bn
- $67.67m
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)
Intellia Therapeutics, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary
Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Brief: Intellia Therapeutics Q2 Net Income USD -106.634 Million
Brief: Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)
Intellia Therapeutics Q1 net loss narrows on lower R&D spending
Brief: Intellia Therapeutics Q1 Net Income USD -96.231 Million
U.S. STOCKS ON THE MOVE-Seagate, GE Healthcare, Bloom Energy
U.S. STOCKS ON THE MOVE-ICON, Old Dominion, Energy companies
U.S. STOCKS ON THE MOVE-Phillips 66, Cognizant, AbbVie
Gene-editing firm Intellia falls on $180 mln stock sale
U.S. RESEARCH ROUNDUP-Commvault Systems, Domino's Pizza, Organon & Co
Intellia launches $150 mln stock offering following gene therapy trial; shares drop
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial (updated)
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
Brief: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)